Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo.

Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, Lai M, Wesenberg A, Ugaonkar S, Levendosky K, Mizenina O, Kleinbeck K, Lifson JD, Peet MM, Lloyd Z, Benson M, Heneine W, O'Keefe BR, Robbiani M, Martinelli E, Grasperge B, Blanchard J, Gettie A, Teleshova N, Fernández-Romero JA, Zydowsky TM.

Nat Commun. 2018 Sep 24;9(1):3881. doi: 10.1038/s41467-018-06349-0.

2.

MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1.

Mizenina O, Hsu M, Jean-Pierre N, Aravantinou M, Levendosky K, Paglini G, Zydowsky TM, Robbiani M, Fernández-Romero JA.

Drug Deliv Transl Res. 2017 Dec;7(6):859-866. doi: 10.1007/s13346-017-0421-4.

PMID:
28812250
3.

An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.

Derby N, Aravantinou M, Kenney J, Ugaonkar SR, Wesenberg A, Wilk J, Kizima L, Rodriguez A, Zhang S, Mizenina O, Levendosky K, Cooney ML, Seidor S, Gettie A, Grasperge B, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero J, Zydowsky TM, Robbiani M.

Drug Deliv Transl Res. 2017 Dec;7(6):840-858. doi: 10.1007/s13346-017-0389-0.

4.

PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo.

Aravantinou M, Frank I, Hallor M, Singer R, Tharinger H, Kenney J, Gettie A, Grasperge B, Blanchard J, Salazar A, Piatak M Jr, Lifson JD, Robbiani M, Derby N.

PLoS One. 2016 Sep 7;11(9):e0161730. doi: 10.1371/journal.pone.0161730. eCollection 2016.

5.

A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo.

Villegas G, Calenda G, Ugaonkar S, Zhang S, Kizima L, Mizenina O, Gettie A, Blanchard J, Cooney ML, Robbiani M, Fernández-Romero JA, Zydowsky TM, Teleshova N.

PLoS One. 2016 Jul 18;11(7):e0159332. doi: 10.1371/journal.pone.0159332. eCollection 2016.

6.

Rectal HSV-2 Infection May Increase Rectal SIV Acquisition Even in the Context of SIVΔnef Vaccination.

Guerra-Pérez N, Aravantinou M, Veglia F, Goode D, Truong R, Derby N, Blanchard J, Grasperge B, Gettie A, Robbiani M, Martinelli E.

PLoS One. 2016 Feb 17;11(2):e0149491. doi: 10.1371/journal.pone.0149491. eCollection 2016.

7.

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations.

Jean-Pierre N, Barnable P, Kizima L, Rodríguez A, Seidor S, Cooney ML, Clark MR, Doncel GF, Robbiani M, Zydowsky TM, Teleshova N, Fernández-Romero JA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):1141-4. doi: 10.1128/AAC.02468-15. Print 2016 Feb.

8.

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.

Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, Kleinbeck K, Bonnaire T, Robbiani M, Zydowsky TM, O'Keefe BR, Fernández-Romero JA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7290-8. doi: 10.1128/AAC.01816-15. Epub 2015 Sep 14.

9.

A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.

Ugaonkar SR, Wesenberg A, Wilk J, Seidor S, Mizenina O, Kizima L, Rodriguez A, Zhang S, Levendosky K, Kenney J, Aravantinou M, Derby N, Grasperge B, Gettie A, Blanchard J, Kumar N, Roberts K, Robbiani M, Fernández-Romero JA, Zydowsky TM.

J Control Release. 2015 Sep 10;213:57-68. doi: 10.1016/j.jconrel.2015.06.018. Epub 2015 Jun 17.

10.

Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection.

Guerra-Pérez N, Frank I, Veglia F, Aravantinou M, Goode D, Blanchard JL, Gettie A, Robbiani M, Martinelli E.

J Immunol. 2015 Mar 1;194(5):2415-23. doi: 10.4049/jimmunol.1402623. Epub 2015 Jan 26.

11.

Preclinical assessments of vaginal microbicide candidate safety and efficacy.

Fernández-Romero JA, Teleshova N, Zydowsky TM, Robbiani M.

Adv Drug Deliv Rev. 2015 Sep 15;92:27-38. doi: 10.1016/j.addr.2014.12.005. Epub 2014 Dec 24. Review.

12.

HSV-2-driven increase in the expression of α4β7 correlates with increased susceptibility to vaginal SHIV(SF162P3) infection.

Goode D, Truong R, Villegas G, Calenda G, Guerra-Perez N, Piatak M, Lifson JD, Blanchard J, Gettie A, Robbiani M, Martinelli E.

PLoS Pathog. 2014 Dec 18;10(12):e1004567. doi: 10.1371/journal.ppat.1004567. eCollection 2014 Dec.

13.

[Microbicides for preventing sexually transmitted infections: Current status and strategies for preclinical evaluation of new candidates].

Fernández Romero JA, Gil PI, Ré V, Robbiani M, Paglini G.

Rev Argent Microbiol. 2014 Jul-Sep;46(3):256-68. doi: 10.1016/S0325-7541(14)70080-X. Epub 2014 Oct 15. Review. Spanish.

14.

Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides.

Kenney J, Derby N, Aravantinou M, Kleinbeck K, Frank I, Gettie A, Grasperge B, Blanchard J, Piatak M Jr, Lifson JD, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1117-24. doi: 10.1089/aid.2014.0207.

15.

A MIV-150/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explants.

Barnable P, Calenda G, Ouattara L, Gettie A, Blanchard J, Jean-Pierre N, Kizima L, Rodríguez A, Abraham C, Menon R, Seidor S, Cooney ML, Roberts KD, Sperling R, Piatak M Jr, Lifson JD, Fernandez-Romero JA, Zydowsky TM, Robbiani M, Teleshova N.

PLoS One. 2014 Sep 26;9(9):e108109. doi: 10.1371/journal.pone.0108109. eCollection 2014.

16.

In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.

Rodríguez A, Kleinbeck K, Mizenina O, Kizima L, Levendosky K, Jean-Pierre N, Villegas G, Ford BE, Cooney ML, Teleshova N, Robbiani M, Herold BC, Zydowsky T, Fernández Romero JA.

Antiviral Res. 2014 Aug;108:88-93. doi: 10.1016/j.antiviral.2014.05.018. Epub 2014 Jun 5.

17.

Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission.

Goode D, Aravantinou M, Jarl S, Truong R, Derby N, Guerra-Perez N, Kenney J, Blanchard J, Gettie A, Robbiani M, Martinelli E.

PLoS One. 2014 May 15;9(5):e97767. doi: 10.1371/journal.pone.0097767. eCollection 2014.

18.

A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV.

Kizima L, Rodríguez A, Kenney J, Derby N, Mizenina O, Menon R, Seidor S, Zhang S, Levendosky K, Jean-Pierre N, Pugach P, Villegas G, Ford BE, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Teleshova N, Zydowsky TM, Robbiani M, Fernández-Romero JA.

PLoS One. 2014 Apr 16;9(4):e94547. doi: 10.1371/journal.pone.0094547. eCollection 2014.

19.

MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection.

Ouattara LA, Barnable P, Mawson P, Seidor S, Zydowsky TM, Kizima L, Rodriguez A, Fernández-Romero JA, Cooney ML, Roberts KD, Gettie A, Blanchard J, Robbiani M, Teleshova N.

Antimicrob Agents Chemother. 2014 May;58(5):2841-8. doi: 10.1128/AAC.01529-13. Epub 2014 Mar 10.

20.

Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques.

Hsu M, Keele BF, Aravantinou M, Krawczyk N, Seidor S, Abraham CJ, Zhang S, Rodriguez A, Kizima L, Derby N, Jean-Pierre N, Mizenina O, Gettie A, Grasperge B, Blanchard J, Piatak MJ Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

PLoS One. 2014 Feb 27;9(2):e89300. doi: 10.1371/journal.pone.0089300. eCollection 2014.

21.

A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.

Hsu M, Aravantinou M, Menon R, Seidor S, Goldman D, Kenney J, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):174-83. doi: 10.1089/AID.2013.0165. Epub 2013 Nov 22.

22.

The frequency of α₄β₇(high) memory CD4⁺ T cells correlates with susceptibility to rectal simian immunodeficiency virus infection.

Martinelli E, Veglia F, Goode D, Guerra-Perez N, Aravantinou M, Arthos J, Piatak M Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M.

J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):325-31. doi: 10.1097/QAI.0b013e31829f6e1a.

23.

A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.

Kenney J, Rodríguez A, Kizima L, Seidor S, Menon R, Jean-Pierre N, Pugach P, Levendosky K, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Zydowsky TM, Robbiani M, Fernández Romero JA.

Antimicrob Agents Chemother. 2013 Aug;57(8):4001-9. doi: 10.1128/AAC.00796-13. Epub 2013 Jun 10.

24.

Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.

Mann A, Friedrich N, Krarup A, Weber J, Stiegeler E, Dreier B, Pugach P, Robbiani M, Riedel T, Moehle K, Robinson JA, Rusert P, Plückthun A, Trkola A.

J Virol. 2013 May;87(10):5868-81. doi: 10.1128/JVI.00152-13. Epub 2013 Mar 13.

25.

In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?

Derby N, Zydowsky T, Robbiani M.

Expert Rev Anti Infect Ther. 2013 Jan;11(1):5-8. doi: 10.1586/eri.12.155. No abstract available.

26.

Simian immunodeficiency virus interactions with macaque dendritic cells.

Teleshova N, Derby N, Martinelli E, Pugach P, Calenda G, Robbiani M.

Adv Exp Med Biol. 2013;762:155-81. doi: 10.1007/978-1-4614-4433-6_6. Review.

27.

An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques.

Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM.

Sci Transl Med. 2012 Sep 5;4(150):150ra123. doi: 10.1126/scitranslmed.3003936.

28.

Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.

Jasny E, Geer S, Frank I, Vagenas P, Aravantinou M, Salazar AM, Lifson JD, Piatak M Jr, Gettie A, Blanchard JL, Robbiani M.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):425-35. doi: 10.1097/QAI.0b013e318266be53.

29.

The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.

Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham CJ, Menon R, Seidor S, Goldman D, Kenney J, Villegas G, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Teleshova N, Robbiani M.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1467-75. doi: 10.1089/AID.2012.0080. Epub 2012 Aug 27.

30.

A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use.

Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, Menon R, Seidor S, Zhang S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1476-84. doi: 10.1089/AID.2012.0087. Epub 2012 Jul 30.

31.

Non-specific microbicide product development: then and now.

Romano JW, Robbiani M, Doncel GF, Moench T.

Curr HIV Res. 2012 Jan 1;10(1):9-18. Review.

32.

Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.

Fernández-Romero JA, Abraham CJ, Rodriguez A, Kizima L, Jean-Pierre N, Menon R, Begay O, Seidor S, Ford BE, Gil PI, Peters J, Katz D, Robbiani M, Zydowsky TM.

Antimicrob Agents Chemother. 2012 Jan;56(1):358-68. doi: 10.1128/AAC.05461-11. Epub 2011 Nov 7.

33.

Myeloid dendritic cells in HIV-1 infection.

Derby N, Martinelli E, Robbiani M.

Curr Opin HIV AIDS. 2011 Sep;6(5):379-84. doi: 10.1097/COH.0b013e3283499d63. Review.

34.

HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target.

Martinelli E, Tharinger H, Frank I, Arthos J, Piatak M Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M.

PLoS Pathog. 2011 Jun;7(6):e1002109. doi: 10.1371/journal.ppat.1002109. Epub 2011 Jun 30.

35.

The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques.

Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M.

J Virol. 2011 Jun;85(11):5504-12. doi: 10.1128/JVI.02422-10. Epub 2011 Mar 16.

36.

Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro.

Begay O, Jean-Pierre N, Abraham CJ, Chudolij A, Seidor S, Rodriguez A, Ford BE, Henderson M, Katz D, Zydowsky T, Robbiani M, Fernández-Romero JA.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):1019-24. doi: 10.1089/AID.2010.0252. Epub 2011 Mar 8.

37.

An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques.

Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, Kizima L, Abraham CJ, Menon R, Seidor S, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M.

PLoS One. 2011 Jan 5;6(1):e15835. doi: 10.1371/journal.pone.0015835.

38.

Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection.

Frank I, Robbiani M.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):204-12. doi: 10.1097/QAI.0b013e3181ff2aa5.

39.

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Vagenas P, Aravantinou M, Williams VG, Jasny E, Piatak M Jr, Lifson JD, Salazar AM, Blanchard JL, Gettie A, Robbiani M.

PLoS One. 2010 Sep 21;5(9):e12891. doi: 10.1371/journal.pone.0012891.

40.

In vivo binding and retention of CD4-specific DARPin 57.2 in macaques.

Pugach P, Krarup A, Gettie A, Kuroda M, Blanchard J, Piatak M Jr, Lifson JD, Trkola A, Robbiani M.

PLoS One. 2010 Aug 27;5(8):e12455. doi: 10.1371/journal.pone.0012455.

41.

A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy.

Crostarosa F, Aravantinou M, Akpogheneta OJ, Jasny E, Shaw A, Kenney J, Piatak M, Lifson JD, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Blanchard J, Gettie A, Robbiani M.

PLoS One. 2009 Nov 30;4(11):e8060. doi: 10.1371/journal.pone.0008060.

42.

Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Vagenas P, Williams VG, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard JL, Gettie A, Robbiani M.

J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):433-42. doi: 10.1097/QAI.0b013e3181b880f3.

43.

Editorial comment.

Robbiani M.

Curr Opin HIV AIDS. 2008 Sep;3(5):533. doi: 10.1097/COH.0b013e32830b5d4c. No abstract available.

PMID:
19373018
44.

Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G.

Trapp S, Derby NR, Singer R, Shaw A, Williams VG, Turville SG, Bess JW Jr, Lifson JD, Robbiani M.

J Virol. 2009 Jan;83(2):884-95. doi: 10.1128/JVI.00023-08. Epub 2008 Nov 12.

45.

Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity.

Turville SG, Aravantinou M, Miller T, Kenney J, Teitelbaum A, Hu L, Chudolij A, Zydowsky TM, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard J, Gettie A, Robbiani M.

PLoS One. 2008 Sep 8;3(9):e3162. doi: 10.1371/journal.pone.0003162.

46.

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics.

Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthésy S, Turville SG, Aravantinou M, Fischer M, Robbiani M, Amstutz P, Trkola A.

PLoS Pathog. 2008 Jul 25;4(7):e1000109. doi: 10.1371/journal.ppat.1000109.

47.

Candida albicans-induced DC activation partially restricts HIV amplification in DCs and increases DC to T-cell spread of HIV.

Vachot L, Williams VG, Bess JW Jr, Lifson JD, Robbiani M.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):398-407. doi: 10.1097/QAI.0b013e3181776bc7.

PMID:
18614931
48.

Current concepts of HIV transmission.

Morrow G, Vachot L, Vagenas P, Robbiani M.

Curr Infect Dis Rep. 2008 May;10(2):133-9.

PMID:
18462588
49.

A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells.

Frank I, Stössel H, Gettie A, Turville SG, Bess JW Jr, Lifson JD, Sivin I, Romani N, Robbiani M.

J Virol. 2008 Jun;82(11):5329-39. doi: 10.1128/JVI.01987-07. Epub 2008 Mar 26.

50.

Feline immunodeficiency virus dendritic cell infection and transfer.

Sprague WS, Robbiani M, Avery PR, O'Halloran KP, Hoover EA.

J Gen Virol. 2008 Mar;89(Pt 3):709-15. doi: 10.1099/vir.0.83068-0.

PMID:
18272762

Supplemental Content

Loading ...
Support Center